Detailed price information for Roivant Sciences Ltd (ROIV-Q) from The Globe and Mail including charting and trades.

Tuesday, Roivant Sciences Ltd. (NASDAQ:ROIV) created Pulmovant to in-license from Bayer AG (OTC:BAYRY) exclusive worldwide rights to develop and commercialize mosliciguat. Bayer received an upfront ...

Moderna to pay Genevant and Arbutus $950 million upfront and an additional $1.3 billion contingent upon a favorable resolution of Moderna’s ...

Roivant Sciences Ltd. (NASDAQ:ROIV) is one of the best biotech stocks to invest in now. On June 16, Pulmovant, a Roivant company, announced the publication of Phase 1 pharmacokinetic/PK data for ...

Moderna jumps after $2.25B settlement with Genevant and Arbutus over LNP patents tied to its COVID-19 and RSV vaccines, ending global litigation.

Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. Pulmovant, a Roivant Sciences subsidiary, has completed enrollment in the Phase 2 PHocus ...

Organon is broadening its presence in dermatology with a deal to acquire Dermavant, a company whose main asset is a commercialized plaque psoriasis drug that could soon expand its approval to include ...

Roivant Sciences Ltd. has seen a slight gain of 10% in its stock over the past 10 months, since my "buy" recommendation last May. The company has a differentiated drug development pipeline targeting ...

Roivant Sciences stock has risen significantly since my initial coverage in 2022, with a positive market response to fiscal year 2025 Q1 earnings. Roivant operates by creating "nimble subsidiaries to ...

Moderna to pay Genevant and Arbutus $950 million upfront and an additional $1.3 billion contingent upon a favorable resolution of Moderna’s ...